ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Apr 28, 2021 12:33 JST
Source:
Eisai
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
Building Dementia Ecosystem
TOKYO, Apr 28, 2021 - (JCN Newswire) - Saitama Resona Bank, Limited, a corporation of the Resona Group, and Eisai Co., Ltd. announced today that both parties have entered into a business alliance agreement for building an ecosystem with the aim of supporting people living with and preventing dementia ("dementia ecosystem"), in order to realize a regional community where citizens of Saitama Prefecture can live with peace of mind for a long time while maintaining their health.
Image of a sustainable community with dementia ecosystem
In Saitama Prefecture, the speed of aging of society is estimated to be at the top level in Japan. Therefore, one of the major issues is making efforts to create a community where people can live with dementia, and prevent the onset of dementia. Through this business alliance, Resona and Eisai will build a "dementia ecosystem" that combines Resona's customer network in Saitama Prefecture and Eisai's wealth of experience and knowledge in drug creation activities and disease awareness activities in the field of dementia, aiming to support Saitama citizens and people working in companies in Saitama prefecture to maintain a healthy life and create a sustainable community.
As the first step in this effort, the customers of the investment trust "SAITAMA RESONA GLOBAL BALANCE PLUS ESG - SaitamaDGs -"(1) handled by Resona will be provided with Eisai's digital tool for self-assessment of brain performance (brain health) "NouKNOWTM" (pronounced "NOH-NOH", non-medical device).(2) We will provide the customers at Resona with opportunities to build assets and contribute to the local community through investment in Saitama Prefecture bonds, etc., and support them to secure their life by providing an opportunity to regularly check brain performance and maintain brain health by improving lifestyle habits.
Furthermore, Resona and Eisai will collaborate with local governments, companies, universities, public institutions, etc. in Saitama Prefecture through the dementia ecosystem, aiming to co-create value for realizing a sustainable community where citizens of the prefecture can live with peace of mind. For example, to reduce and eliminate anxieties, to enable them to lead a prosperous retirement life, or to enable companies in Saitama Prefecture to engage in efforts for health and productivity management.
(1) This is an investment trust in which Resona makes international diversified investments and ESG investments as a medium- to long-term asset formation support for its customer, as well as investments in Saitama prefectural bonds. Resona provides its customers with the opportunity to participate in the realization of the SDGs and contribute to the local community and society in Saitama Prefecture through their asset management. Resona will meet the needs of its customers who want to contribute to the creation of a society that can withstand the COVID-19 pandemic, by donating a part of the profits of the product to Saitama Prefecture's "COVID-19 Infection Countermeasure Fund" which is the initiative taken by the Saitama Prefecture Office to support the activities of medical professionals and medical institutions.
(2) "NouKNOW" is conducted through a simple card test using a PC or tablet device to quantitatively measure brain performance in four tests evaluating psychomotor function, attention, learning and memory, and working memory. This digital tool allows users to self-assess independently and in a short time frame (approx.15 minutes), enabling regular assessments in instances such as daily life and health checkups. On the results screen, a score (brain performance index (BPI)) - as a measurement of quantified brain performance aspects such as memorization, cognition, and decision - appears along with lifestyle advice for maintaining brain performance.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Power Receives Contract for Large-Scale GTCC Project with 2,800 MW Total Output for Taiwan's Tung Hsiao Power Plant
Sep 05, 2025 21:47 JST
Hitachi announces historic $1 billion USD manufacturing investment to power America's energy future through production of critical grid infrastructure
Sep 05, 2025 21:00 JST
NEC participates in Locked Shields 2025 hosted by the NATO Cooperative Cyber Defence Centre of Excellence
Sep 05, 2025 11:20 JST
TANAKA Announces Executive Appointment
Sep 05, 2025 03:00 JST
Honda to Begin Sales of All-new Prelude
Sep 04, 2025 13:20 JST
Signing of Agreement with Yamaguchi Prefecture and Iwakuni City to Construct Module Pack Plant of Automotive Cylindrical Lithium-Ion Batteries
Sep 04, 2025 11:54 JST
NEC to begin proof of concept for early earthquake detection and analysis in Colombia
Sep 04, 2025 11:15 JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sep 04, 2025 10:56 JST
Honda Premieres a New Color Option for Four Large-size Outboard Motors at HISWA In-Water Boat Show 2025 in the Netherlands
Sep 03, 2025 23:50 JST
Toyota Joins TOKYO H2 Project Aiming to Make Tokyo a Global Leader in Hydrogen
Sep 03, 2025 22:39 JST
Honda Running Team Member, Nagiya Mori, Selected to Represent Japan in World Athletics Championships Tokyo 25 (WCH Tokyo 25) Men's 5000m Event
Sep 03, 2025 12:30 JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sep 03, 2025 11:32 JST
Anime Tokyo Station: TV Anime "SPY x FAMILY" Special Exhibition, Period: August 16 - November 9, 2025
Sep 03, 2025 11:00 JST
Fujitsu, 1Finity and Arrcus sign strategic partnership agreement to deliver innovative network solutions for AI infrastructure
Sep 03, 2025 10:58 JST
Mitsubishi Corporation Invests in Commonwealth Fusion Systems, a US Fusion Energy Start-up from MIT
Sep 02, 2025 12:50 JST
Hitachi has been certified as a Gold Partner of Scaled Agile, Inc., the provider of the large-scale agile framework "SAFe(R)"
Sep 02, 2025 11:50 JST
ABVC BioPharma Receives $450,000 in Licensing Payments from OncoX BioPharma in Q3 2025
Sep 01, 2025 22:28 JST
DENSO Signs Agreement to Transfer Part of Its Ceramic Product Business
Sep 01, 2025 20:52 JST
Honda to Provide Official Vehicles for World Athletics Championships Tokyo 25 as Official Global Partner
Sep 01, 2025 13:50 JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Sep 01, 2025 13:44 JST
More Latest Release >>
Related Release
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
9/4/2025 10:56:00 AM JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
9/3/2025 11:32:00 AM JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
9/1/2025 1:44:00 PM JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
8/29/2025 6:17:00 PM JST
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
8/25/2025 7:30:00 PM JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
8/18/2025 9:11:00 AM JST
Revenue of LEQEMBI(R) (Preliminary Basis)
7/31/2025 6:27:00 PM JST
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
7/31/2025 9:30:00 AM JST
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
7/31/2025 9:20:00 AM JST
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
7/31/2025 9:10:00 AM JST
More Press release >>